Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
← catalyst calendarSponsored by Amgen (industry) · AMGN — their whole pipeline →. With Novartis.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
457actual
Sites
119
Countries
Belgium, Canada, Colombia +13
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-07-19 | actual | When the study began enrolling |
| Primary completion | 2025-11-19 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-11-19 | estimated | The whole study's end, after follow-up |
| First posted | 2019-02-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Migraine
Interventions
- Drug: Erenumab Dose 1 — also filed as AMG334, Aimovig®
- Drug: Erenumab Dose 2 — also filed as AMG 334, Aimovig®
- Drug: Erenumab Dose 3 — also filed as AMG 334, Aimovig®
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from baseline in MMDs
measured Baseline through week 12 of the double blind treatment phase
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed